KRAS and cancer: Consistent with this, KRAS proximity to EGFR and its canonical downstream kinases, Raf1 and PI3K P110α decreased with SNARE TKO and increased with SNORD50A/B KO in cancer cells with activating oncogenic KRAS mutations (Fig. 5a, b, c).